Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Genetics

Reviewed as evidence on: Statin / lipid-lowering use (incl. CETP inhibitors) and dementia incidence 5 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background and objectives The association of statin initiation with incident Alzheimer disease (AD) dementia and cognitive decline by the APOE ε4 allele is unknown. Our objective was to examine whether the association of statin initiation with incident AD dementia and cognitive decline differs by the APOE ε4 allele. Methods This population-based longitudinal cohort study was conducted in 4 urban communities in Chicago, IL, United States, consisting of 4,807 participants. Statin initiation is based on the inspection of medications during home assessments. Clinical diagnosis for incident AD used the NINCDS-ADRDA criteria, and longitudinal measurements of global cognition consisted of episodic memory, perceptual speed, and the Mini-Mental State Examination tests. Results The study participants had a mean age of 72 years, consisting of 63% female individuals and 61% non-Hispanic Black individuals. During the study period, 1,470 (31%) participants reported statin initiation. In a covariate-adjusted competing risk model, statin initiation was associated with a reduced risk of incident clinical AD [hazard ratio (HR) 0.81 (95% CI 0.70-0.94)] compared with nonusers. This association was statistically significantly lower ( p interaction = 0.015) among participants with the APOE ε4 allele [HR 0.60 (95% CI 0.49-0.74)] compared with those without the APOE ε4 allele [HR 0.96 (95% CI 0.82-1.12)]. The annual decline in global cognition (β = 0.021, 95% CI 0.007-0.034) and episodic memory (β = 0.020, 95% CI 0.007-0.033) was also substantially slower among participants with the APOE ε4 allele after statin initiation compared with nonusers. However, the association of statin initiation with cognitive decline was not significant among those without the APOE ε4 allele. Discussion Our findings suggest that statins might be associated with a lower risk of incident AD among individuals with the APOE ε4 allele. The benefits of statin therapy need further consideration in randomized clinical trials, especially among those with the APOE ε4 allele. Classification of evidence This study provides Class II evidence that among those aged 65 years or older, statin initiation was associated with a reduced risk of Alzheimer disease, especially in the presence of an APOE -e4 allele.

What this study adds

Evidence grade: Early

This is a follow-up (cohort) study of 4,807 participants. In this cohort, statin initiation was associated with a reduced risk of incident clinical Alzheimer's disease compared with nonusers. Reported effect size: Alzheimer's HR 0.81 (95% CI 0.70-0.94) overall; 0.60 (0.49-0.74) in APOE ε4 carriers; 0.96 (0.82-1.12) in non-carriers.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rajan, K. B., Mcaninch, E. A., Wilson, R. S., Dhana, A., Evans-Lacko, S., & Evans, D. A. (2024). Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults. Neurology. https://doi.org/10.1212/WNL.0000000000209168

Vancouver

Rajan KB, Mcaninch EA, Wilson RS, Dhana A, Evans-Lacko S, Evans DA. Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults. Neurology. 2024. doi:10.1212/WNL.0000000000209168. PMID: 38447103.

BibTeX

@article{rajan2024-38447103,
  author  = {Rajan, K. B. and Mcaninch, E. A. and Wilson, R. S. and Dhana, A. and Evans-Lacko, S. and Evans, D. A.},
  title   = {{Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/WNL.0000000000209168},
  pmid    = {38447103},
  url     = {https://doi.org/10.1212/WNL.0000000000209168}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this cohort, statin initiation was associated with a reduced risk of incident clinical Alzheimer's disease compared with nonusers. The association was stronger among participants with the APOE ε4 allele than among those without it.

Study details

Limitations

Observational with healthy-user bias possible; statin use assessed by medication inspection at home visits; single urban cohort; conflicts with larger null target-trial emulations.

How this study scored 66/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 65 of the 98 points it could be judged on, which is 66 of 100. Total 66 of 100.65 of the 98 points we could judge = 66 of 100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 65 of the 98 points we could judge it on, which is 66 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 3 / 4 4,807 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 34 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.5 citations a year over 4 year(s) since 2024
Impact for its field and year 4 / 6 Cited 9.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 34 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Denis A. Evans: h-index 99 (OpenAlex, whole career)
Institution's track record 2 / 3 Stanford Medicine: institution h-index 1,604 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38447103)
Free to read — / 2 Access not recorded — left out of this score
Points 65 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 65 of the 98 points we could judge it on is 66 out of 100.
Total 66 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Genetics from nearby years

Also tagged “statin-lipid-lowering-and-dementia”

5 studies in the library carry the topic tag “statin-lipid-lowering-and-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Genetics

See all studies in Genetics →